Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
0 hedge funds and large institutions have $0 invested in Kezar Life Sciences in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 43 closing their positions.
60.09% less ownership
Funds ownership: 60.09% → 0% (-60%)
100% less funds holding
Funds holding: 43 → 0 (-43)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $32.8M → $0 (-$32.8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 43
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$5.35M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$5.32M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.93M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$2.16M |
| 5 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
-$1.8M |
KZR Hedge Fund Activity: Q2 2026 in Review
0 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2026, worth a combined $0 — down 100% from $32.8M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of KZR and 0 opened new positions — a net loss of 43 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BML Capital Management, exiting entirely with an estimated $5.35M sold.
- 0 institutional investors held Kezar Life Sciences (KZR) as of Q2 2026, down from 43 in Q1 2026.
- Funds reported $0 of Kezar Life Sciences stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new Kezar Life Sciences positions in Q2 2026 and 43 closed out, a net change of -43 holders.
- The largest Kezar Life Sciences seller in Q2 2026 was BML Capital Management, an estimated $5.35M sold.
Based on aggregated 13F filings for Q2 2026.